Synercid (quinupristin-dalfopristin) is now available for emergency use

February 1996

Rhone-Poulenc Rorer's investigational antibiotic Synercid (quinupristin-dalfopristin) is now available for emergency use...for certain resistant Gram-positive infections.

It's being used for vancomycin-resistant enterococci (VRE)...and methicillin-resistant Staph aureus (MRSA) or Staph epidermidis in patients who can't take vancomycin. It also seems to be active against penicillin-resistant pneumococcus.

Both quinupristin and dalfopristin are in a new class of antibiotics called streptogramins. The combination has synergistic effects. (Hence the name Synercid.)

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote